Melatonin for Autistic Children: UK Sleep Guide

Can melatonin help autistic children sleep?

Melatonin may help some autistic children with persistent sleep problems. NICE says it can be considered when a sleep plan has not helped enough and sleep problems affect the child or family, following consultation with a specialist. Benefits, side effects and ongoing need should be reviewed regularly. Read NICE’s sleep recommendations.

In the UK, melatonin is a prescription medicine. It comes in different forms, including standard and slow-release tablets and liquid. Your child’s clinician should explain whether it is appropriate and which preparation they recommend. NHS information about melatonin.

Understanding the sleep problem

Tell the clinician whether the difficulty is settling, repeated waking, waking very early, or a combination. Mention snoring or breathing concerns, discomfort, medicines, anxiety and anything in the sleeping environment that troubles your child. NICE recommends an assessment of the pattern and possible causes before agreeing support. Sleep difficulties are not a parenting failure.

What does the research show?

Falling asleep and total sleep time are different outcomes

The MENDS trial studied children with neurodevelopmental disorders whose severe sleep problems persisted after behavioural advice. Compared with placebo, immediate-release melatonin increased diary-recorded sleep by about 22 minutes, on average. Children fell asleep sooner, but some woke earlier too. The results do not mean every child will gain the same amount of sleep. Read the MENDS trial report.

A later trial of prolonged-release melatonin included 125 children, mostly autistic, whose sleep had not improved with behavioural support. After 13 weeks, the adjusted difference compared with placebo was approximately 33 minutes in total sleep time and 25 minutes in time taken to fall asleep. These are group averages from one trial. They do not establish that a particular product is best for an individual child. Read the prolonged-release trial.

A 2023 systematic review of 15 studies found improvements in sleep duration, sleep onset and sleep efficiency, but substantial differences between studies limit how confidently the pooled results apply to an individual. The overall result for night waking was not statistically clear. Read the systematic review.

What is Slenyto?

Slenyto is one brand of prolonged-release melatonin. Its current UK product information includes insomnia in autistic children aged 2 to 18 when sleep measures have been insufficient, alongside other specified indications. A medicine’s licence describes approved uses; it is not a guarantee of benefit or a reason to choose it without an individual assessment. Check the current UK product information.

Which prescription option is appropriate?

Immediate-release and prolonged-release preparations work differently. Licensing depends on the exact product, age and condition: some immediate-release preparations have specific licensed uses. For example, Adaflex’s UK product information includes insomnia in children aged 6 to 17 with ADHD after insufficient sleep measures. Ask the prescriber to explain the choice and whether the proposed use is within the product’s licence. Do not switch preparations, alter tablets or change timing or dose without checking with the prescriber or pharmacist.

Online supplements or products bought abroad should not replace a child’s prescribed medicine. Take any supplement packaging and a list of other medicines to the pharmacist or clinician so they can check suitability and interactions.

How to ask for NHS sleep support

Start with your GP or the team already supporting your child. Explain the effect on daytime activities, school, family sleep and safety. Ask who provides children’s sleep support locally and how specialist assessment is arranged. Local pathways differ; an autism assessment referral does not itself arrange a melatonin prescription.

You can keep these questions on paper. No information about your child needs to be sent to SENDPath. Our Kent and Medway help-while-waiting guide lists other local support routes.

A sleep plan that fits your family

A clinician can help develop a plan that considers your child’s needs and your family’s circumstances. A short sleep diary can show patterns and help assess whether a change is useful. NICE recommends recording sleep and wakefulness for two weeks and using it to review the plan. Ask for adaptations if keeping a diary or following the plan is difficult. It should support you, not become another barrier to help.

If sleep is still difficult

Contact the prescriber to review the original aim, what has changed and any unwanted effects. Persistent difficulties need reassessment; do not keep increasing the dose yourself. Note what matters in everyday life, such as morning alertness and whether nights are more manageable, as well as the time spent asleep.

Side effects and longer-term uncertainty

Reported side effects include drowsiness, fatigue, headache, irritability and mood changes. The product leaflet explains risks and interactions for the prescribed preparation. Speak to the clinician or pharmacist about new symptoms or morning sleepiness. Read the NHS overview.

A follow-up study of 80 children and adolescents, mostly autistic, examined prolonged-release melatonin for up to two years. It did not find delayed growth or puberty among those assessed. That is reassuring within the study’s limits, but its size, duration and follow-up design cannot rule out every long-term risk. Regular review remains necessary. Read the two-year follow-up.

A useful next step

Choose the questions above that matter most to your family and take them to your child’s clinician. The aim is an agreed sleep plan, a clear way to assess benefit, and a named route for help if the plan is not working.

Sources, authorship and corrections

Written by SENDPath. Sources and UK product information checked on 7 September 2026. This is a parent-facing summary, not an independent clinical review. Original guidance and research are linked beside the relevant claims.

Correction, 7 September 2026: an earlier version incorrectly described a withdrawn Cochrane protocol as a completed review supporting treatment. That claim has been removed. We also removed product-superiority language, corrected the blanket description of immediate-release products as unlicensed, and clarified the limits of long-term evidence.

Suggest a correction · About the limits of our health information